Effects of carvedilol and metoprolol on expression of autoantibodies against cardiac adrenergic receptors in aged patients with chronic heart failure and ventricular arrhythmia
10.3760/cma.j.issn.0253-3758.2010.07.003
- VernacularTitle:卡维地洛对老年慢性心力衰竭合并室性心律失常患者血清肾上腺素受体自身抗体的影响
- Author:
Xiao-Dong LI
1
;
Jian-Chun WANG
;
Lin YE
;
Yong ZHAO
;
Nan-Nan ZHOU
;
Xi ZHU
Author Information
1. 山东大学附属省立医院
- Keywords:
Heart failure,congestive;
Arrhythmia;
Receptors,adrenergic;
Autoantibodies
- From:
Chinese Journal of Cardiology
2010;38(7):584-587
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of carvedilol and metoprolol on the expression of autoantibodies against cardiac β1,β2 and α1, adrenergic receptors in aged patients with chronic heart failure (CHF) and ventricular arrhythmia (VA). Methods Sixty-eight patients with CHF and VA were randomly divided metoprolol treatment group or carvedilol treatment group on the basis of digoxin and diuretic treatment. All patients were followed up for six months cardiac function was monitored by echocardiography, VA by Holter and the three autoantibodies by enzyme-linked immunosorbent assay ( ELJSA). Results (1) Systolic blood pressure and brain natriuretic peptide (BNP) were significantly lower in carvedilol group than that in metoprolol group (P < 0.05). (2) The positive ratio of autoantibodies against the cardiacβ1 adrenergic receptor was significantly decreased compared with that of pre-treatment ( P < 0.05) in metoprolol group. The positive ratios of autoantibodies against cardiac β1,β2 and α1-adrenergic receptors were all significantly decreased compared with that of pre-treatment (P <0. 01) in carvedilol group. Moreover, the incidence of VA was significantly decreased in carvedilol group ( P < 0.05 ) but not in metoprolol group. Conclusion Carvedilol is superior to metoprolol on decreasing the incidence of VA in aged patients with chronic heart failure and ventricular arrhythmia.
